This is the authors' abstract. We don't add key points for this paper.
This Viewpoint proposes policy options for payers and the federal government to incentivize pharmaceutical manufacturers to adopt value-based pricing of prescription drugs commensurate with the value they bring to patients.
No takes yet. Share an insight, caveat, or question.
Bach et al. (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: